Cardiovascular Diseases

Novartis sends out orphan disease drug to LifeMax Labs LifeMax Laboratories, biotech based in San Francisco is given an authorization of a treatment by Novartis for Netherton syndrome, an orphan genetic disorder. Focus of treatment is on managing symptoms and avoiding skin infections and other complications. LifeMax Labs gets the global rights to develop, manufacture, and market BPR277, the treatment for atopic dermatitis and Netherton syndrome. Novartis will get an upfront payment, development and regulatory milestones and royalties on net sales in exchange. After acing phase 3 trial, Pfizer considers ATTR cardiomyopathy filing for tafamidis Tafamidis for an...